- Raised $39.3M Public Offering, Feb 2021
- Raised $27.5M Public Offering, Apr 2019
- Raised $6M convertible note led by Neurolief Ltd., Mar 2026
About
BrainsWay is a global medical technology company focused on developing cutting-edge medical devices that help advance the field of mental healthcare. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology is used for the non-invasive treatment of major depressive disorder (including reduction of anxiety symptoms), obsessive-compulsive disorder (OCD), and smoking addiction. The company's technology is based on patents filed by the U.S. National Institutes of Health (NIH) and by the company, holding an exclusive license from the NIH for the patent and its technology. BrainsWay's Deep TMS system has received FDA clearance for these indications and CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions.
Funding history · 15 rounds · $153.4M total
Offices
Q&A
- What is BrainsWay's primary focus?
- BrainsWay is a global medical technology company focused on developing cutting-edge medical devices for advanced noninvasive neurostimulation treatments for mental health disorders.
- When was BrainsWay founded and where is its headquarters located?
- BrainsWay was founded in 2003 and its headquarters are located in Jerusalem, Israel.
- What is BrainsWay's core technology?
- BrainsWay's core technology is its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform, used for non-invasive treatment of major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction.
- What is the status of BrainsWay's Deep TMS system regarding regulatory clearances?
- BrainsWay's Deep TMS system has received FDA clearance for major depressive disorder, OCD, and smoking addiction, and CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions.
- What was BrainsWay's most recent public offering?
- In May 2025, BrainsWay completed a Public Offering, raising $14,260,290.
- What was BrainsWay's most recent convertible debt financing?
- In March 2026, BrainsWay secured $6,000,000 in Convertible Debt from Neurolief Ltd.
- What was BrainsWay's most recent equity investment?
- In July 2026, BrainsWay received $3,000,000 in a Secondary Round from Radial Health and Sound Minds Behavioral.
- How many employees does BrainsWay currently have?
- BrainsWay has 51-200 employees.
Team · 25
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainsway.com |
|---|---|
| linkedin.com/company/3253269 | |
| Wikipedia | en.wikipedia.org/wiki/Brainsway |
| Wikidata | wikidata.org/wiki/Q2913953 |
Identifiers & details
| Legal name | BrainsWay Ltd. |
|---|---|
| Founded | 2003 |
| Employees (exact) | 129 |
| Wikidata QID | Q2913953 |
Radar intelligence
Patents
| EPO | 19 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | brainsway.com |
|---|
Wikidata
| QID | Q2913953 |
|---|
Certificate / subdomain footprint
| Subdomains | 32 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513890764 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2006-11-07 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | הרטום 16 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-01 | עדכון הפרה |